Cwm LLC Raises Stock Position in AngioDynamics, Inc. (NASDAQ:ANGO)

Cwm LLC lifted its stake in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 981.3% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 9,732 shares of the medical instruments supplier’s stock after acquiring an additional 8,832 shares during the quarter. Cwm LLC’s holdings in AngioDynamics were worth $76,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Quarry LP increased its position in shares of AngioDynamics by 75.1% during the second quarter. Quarry LP now owns 6,047 shares of the medical instruments supplier’s stock worth $37,000 after acquiring an additional 2,594 shares during the period. Mackenzie Financial Corp purchased a new position in shares of AngioDynamics during the second quarter worth approximately $80,000. SG Americas Securities LLC purchased a new position in shares of AngioDynamics during the third quarter worth approximately $103,000. AE Wealth Management LLC purchased a new position in shares of AngioDynamics during the second quarter worth approximately $87,000. Finally, State Board of Administration of Florida Retirement System increased its position in shares of AngioDynamics by 44.1% during the first quarter. State Board of Administration of Florida Retirement System now owns 15,627 shares of the medical instruments supplier’s stock worth $92,000 after acquiring an additional 4,780 shares during the period. 89.43% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on ANGO shares. Canaccord Genuity Group reduced their target price on shares of AngioDynamics from $13.00 to $12.00 and set a “buy” rating on the stock in a research report on Friday, October 4th. HC Wainwright reissued a “buy” rating and set a $14.00 price objective on shares of AngioDynamics in a report on Friday, October 4th.

Insider Buying and Selling at AngioDynamics

In other news, CEO James C. Clemmer bought 20,000 shares of the stock in a transaction on Monday, October 7th. The stock was bought at an average cost of $6.03 per share, for a total transaction of $120,600.00. Following the completion of the purchase, the chief executive officer now directly owns 681,582 shares in the company, valued at approximately $4,109,939.46. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders bought a total of 22,568 shares of company stock worth $135,847 over the last three months. Corporate insiders own 5.10% of the company’s stock.

AngioDynamics Stock Down 5.1 %

Shares of ANGO stock opened at $6.73 on Friday. The firm has a market cap of $269.57 million, a price-to-earnings ratio of -1.39 and a beta of 0.65. The company’s 50 day moving average is $7.15 and its 200 day moving average is $6.68. AngioDynamics, Inc. has a 52-week low of $5.26 and a 52-week high of $8.25.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings data on Thursday, October 3rd. The medical instruments supplier reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.04. The company had revenue of $67.50 million for the quarter, compared to analyst estimates of $67.93 million. AngioDynamics had a negative net margin of 83.95% and a negative return on equity of 5.86%. AngioDynamics’s revenue was down 14.2% compared to the same quarter last year. During the same period last year, the company posted ($0.12) earnings per share. Analysts anticipate that AngioDynamics, Inc. will post -0.41 EPS for the current fiscal year.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.